Last reviewed · How we verify
Fluorouracil Implants
Fluorouracil implants work by releasing fluorouracil, a thymidylate synthase inhibitor, which interferes with DNA synthesis and function.
Fluorouracil implants work by releasing fluorouracil, a thymidylate synthase inhibitor, which interferes with DNA synthesis and function. Used for Adjuvant treatment of resectable rectal cancer.
At a glance
| Generic name | Fluorouracil Implants |
|---|---|
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Drug class | Antineoplastic |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, leading to the depletion of thymidine triphosphate and the disruption of DNA synthesis and function. This results in the inhibition of cancer cell growth and proliferation.
Approved indications
- Adjuvant treatment of resectable rectal cancer
Common side effects
- Mucositis
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Neutropenia
- Anemia
- Thrombocytopenia
- Infection
- Pain
Key clinical trials
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer (EARLY_PHASE1)
- FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma (PHASE2)
- Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver (PHASE2)
- FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis (PHASE2)
- Effect of Subconjunctival 5-fluorouracil on the Outcome of Ahmed Valve in Neovascular Glaucoma (NA)
- mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |